Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round.

The fundraise was led by Menlo Ventures, including investment from their Anthology Fund, a joint partnership with Anthropic to identify and back promising AI companies, with participation from new investors Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and others. It also included existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam, among others.

Chai Discovery builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, the fundamental building blocks of life. Its mission is to transform biology from science into engineering.